Listed

Adaptimmune Therapeutics PLC

ADAPYOTCCIK 1621227HealthcareFiscal year ends Dec 31

Latest reported revenue, Q2 FY2025$13.7mRevenue, Q2 FY2025, three months to 2025-06-30$13.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-08-13, accession 0001558370-25-011307.Report this figureThree months to Jun 30, 2025, from the 10-Q filed Aug 13, 2025.

Latest quarter: Q2 FY2025

Three months to Jun 30, 2025, against the same quarter a year earlier.

  • Revenue$13.7mRevenue, Q2 FY2025, three months to 2025-06-30$13.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-08-13, accession 0001558370-25-011307.Report this figure−89.3% on a year earlier
  • Gross marginnot reported (Gross profit not reported)No year-earlier figure to compare
  • Operating margin−221.5%Operating margin, Q2 FY2025, three months to 2025-06-30. operating income / revenueOperating income: −$30.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-13, accession 0001558370-25-011307.Revenue: $13.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-08-13, accession 0001558370-25-011307.Report this figure−275.0 pts on a year earlier
  • Net margin−221.8%Net margin, Q2 FY2025, three months to 2025-06-30. net income / revenueNet income: −$30.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-08-13, accession 0001558370-25-011307.Revenue: $13.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-08-13, accession 0001558370-25-011307.Report this figure−276.0 pts on a year earlier
  • Diluted EPS−$0.02Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.02 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-13, accession 0001558370-25-011307.Report this figureSign changed from a year earlier
  • Free cash flow−$34.9mFree cash flow, Q2 FY2025, three months to 2025-06-30. operating cash flow − capital expenditureOperating cash flow: −$34.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-13, accession 0001558370-25-011307. Derived: 6-month figure less the 3-month figure.Capital expenditure: $75.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-08-13, accession 0001558370-25-011307. Derived: 6-month figure less the 3-month figure.Report this figureSign changed from a year earlier

Last eight quarters

Full statements
Revenue$13.7mOperating margin −221.5%
Diluted EPS−$0.02, Q2 FY2025
Free cash flow−$34.9m, Q2 FY2025
Adaptimmune Therapeutics PLC, key figures for the last eight quarters
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Shape over the periods
Revenue$m7.3Revenue, Q3 FY2023, three months to 2023-09-30$7.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2024-11-13, accession 0001558370-24-015532.Report this figure0.2Revenue, Q4 FY2023, three months to 2023-12-31$231.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-24, accession 0001558370-25-003544. Derived: 12-month figure less the 9-month figure.Report this figure5.7Revenue, Q1 FY2024, three months to 2024-03-31$5.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-05-13, accession 0001558370-25-007571.Report this figure128Revenue, Q2 FY2024, three months to 2024-06-30$128.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-08-13, accession 0001558370-25-011307.Report this figure40.9Revenue, Q3 FY2024, three months to 2024-09-30$40.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2024-11-13, accession 0001558370-24-015532.Report this figure3.2Revenue, Q4 FY2024, three months to 2024-12-31$3.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-24, accession 0001558370-25-003544. Derived: 12-month figure less the 9-month figure.Report this figure7.3Revenue, Q1 FY2025, three months to 2025-03-31$7.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-05-13, accession 0001558370-25-007571.Report this figure13.7Revenue, Q2 FY2025, three months to 2025-06-30$13.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-08-13, accession 0001558370-25-011307.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%(637.1%)Operating margin, Q3 FY2023, three months to 2023-09-30. operating income / revenueOperating income: −$46.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-13, accession 0001558370-24-015532.Revenue: $7.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2024-11-13, accession 0001558370-24-015532.Report this figure(21582.7%)Operating margin, Q4 FY2023, three months to 2023-12-31. operating income / revenueOperating income: −$49.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-24, accession 0001558370-25-003544. Derived: 12-month figure less the 9-month figure.Revenue: $231.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-24, accession 0001558370-25-003544. Derived: 12-month figure less the 9-month figure.Report this figure(867.6%)Operating margin, Q1 FY2024, three months to 2024-03-31. operating income / revenueOperating income: −$49.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-13, accession 0001558370-25-007571.Revenue: $5.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-05-13, accession 0001558370-25-007571.Report this figure53.6%Operating margin, Q2 FY2024, three months to 2024-06-30. operating income / revenueOperating income: $68.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-13, accession 0001558370-25-011307.Revenue: $128.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-08-13, accession 0001558370-25-011307.Report this figure(35.9%)Operating margin, Q3 FY2024, three months to 2024-09-30. operating income / revenueOperating income: −$14.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-13, accession 0001558370-24-015532.Revenue: $40.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2024-11-13, accession 0001558370-24-015532.Report this figure(2281.8%)Operating margin, Q4 FY2024, three months to 2024-12-31. operating income / revenueOperating income: −$73.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-24, accession 0001558370-25-003544. Derived: 12-month figure less the 9-month figure.Revenue: $3.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-24, accession 0001558370-25-003544. Derived: 12-month figure less the 9-month figure.Report this figure(627.8%)Operating margin, Q1 FY2025, three months to 2025-03-31. operating income / revenueOperating income: −$45.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-13, accession 0001558370-25-007571.Revenue: $7.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-05-13, accession 0001558370-25-007571.Report this figure(221.5%)Operating margin, Q2 FY2025, three months to 2025-06-30. operating income / revenueOperating income: −$30.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-13, accession 0001558370-25-011307.Revenue: $13.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-08-13, accession 0001558370-25-011307.Report this figure
Net margin%(623.0%)Net margin, Q3 FY2023, three months to 2023-09-30. net income / revenueNet income: −$45.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-13, accession 0001558370-24-015532.Revenue: $7.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2024-11-13, accession 0001558370-24-015532.Report this figure(20743.3%)Net margin, Q4 FY2023, three months to 2023-12-31. net income / revenueNet income: −$47.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-24, accession 0001558370-25-003544. Derived: 12-month figure less the 9-month figure.Revenue: $231.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-24, accession 0001558370-25-003544. Derived: 12-month figure less the 9-month figure.Report this figure(854.2%)Net margin, Q1 FY2024, three months to 2024-03-31. net income / revenueNet income: −$48.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-08-13, accession 0001558370-25-011307.Revenue: $5.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-05-13, accession 0001558370-25-007571.Report this figure54.2%Net margin, Q2 FY2024, three months to 2024-06-30. net income / revenueNet income: $69.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-08-13, accession 0001558370-25-011307.Revenue: $128.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-08-13, accession 0001558370-25-011307.Report this figure(43.1%)Net margin, Q3 FY2024, three months to 2024-09-30. net income / revenueNet income: −$17.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-13, accession 0001558370-24-015532.Revenue: $40.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2024-11-13, accession 0001558370-24-015532.Report this figure(2303.4%)Net margin, Q4 FY2024, three months to 2024-12-31. net income / revenueNet income: −$74.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-24, accession 0001558370-25-003544. Derived: 12-month figure less the 9-month figure.Revenue: $3.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-24, accession 0001558370-25-003544. Derived: 12-month figure less the 9-month figure.Report this figure(653.2%)Net margin, Q1 FY2025, three months to 2025-03-31. net income / revenueNet income: −$47.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-08-13, accession 0001558370-25-011307.Revenue: $7.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-05-13, accession 0001558370-25-007571.Report this figure(221.8%)Net margin, Q2 FY2025, three months to 2025-06-30. net income / revenueNet income: −$30.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-08-13, accession 0001558370-25-011307.Revenue: $13.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-08-13, accession 0001558370-25-011307.Report this figure
Diluted EPS$ per share(0.03)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$0.03 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-13, accession 0001558370-24-015532.Report this figurenot reported (Diluted EPS not reported)(0.03)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$0.03 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-13, accession 0001558370-25-007571.Report this figure0.04Diluted EPS, Q2 FY2024, three months to 2024-06-30$0.04 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-13, accession 0001558370-25-011307.Report this figure(0.01)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.01 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-13, accession 0001558370-24-015532.Report this figurenot reported (Diluted EPS not reported)(0.03)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.03 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-13, accession 0001558370-25-007571.Report this figure(0.02)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.02 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-13, accession 0001558370-25-011307.Report this figure
Free cash flow$m(45.4)Free cash flow, Q3 FY2023, three months to 2023-09-30. operating cash flow − capital expenditureOperating cash flow: −$45.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-13, accession 0001558370-24-015532. Derived: 9-month figure less the 6-month figure.Capital expenditure: $289.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-11-13, accession 0001558370-24-015532. Derived: 9-month figure less the 6-month figure.Report this figure(15.5)Free cash flow, Q4 FY2023, three months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: −$14.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-24, accession 0001558370-25-003544. Derived: 12-month figure less the 9-month figure.Capital expenditure: $827.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-03-24, accession 0001558370-25-003544. Derived: 12-month figure less the 9-month figure.Report this figure(32.1)Free cash flow, Q1 FY2024, three months to 2024-03-31. operating cash flow − capital expenditureOperating cash flow: −$31.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-13, accession 0001558370-25-007571.Capital expenditure: $102.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-05-13, accession 0001558370-25-007571.Report this figure47.0Free cash flow, Q2 FY2024, three months to 2024-06-30. operating cash flow − capital expenditureOperating cash flow: $47.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-13, accession 0001558370-25-011307. Derived: 6-month figure less the 3-month figure.Capital expenditure: $422.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-08-13, accession 0001558370-25-011307. Derived: 6-month figure less the 3-month figure.Report this figure(54.6)Free cash flow, Q3 FY2024, three months to 2024-09-30. operating cash flow − capital expenditureOperating cash flow: −$54.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-13, accession 0001558370-24-015532. Derived: 9-month figure less the 6-month figure.Capital expenditure: $143.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-11-13, accession 0001558370-24-015532. Derived: 9-month figure less the 6-month figure.Report this figure(34.4)Free cash flow, Q4 FY2024, three months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$34.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-24, accession 0001558370-25-003544. Derived: 12-month figure less the 9-month figure.Capital expenditure: $219.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-03-24, accession 0001558370-25-003544. Derived: 12-month figure less the 9-month figure.Report this figure(67.8)Free cash flow, Q1 FY2025, three months to 2025-03-31. operating cash flow − capital expenditureOperating cash flow: −$66.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-13, accession 0001558370-25-007571.Capital expenditure: $1.2m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-05-13, accession 0001558370-25-007571.Report this figure(34.9)Free cash flow, Q2 FY2025, three months to 2025-06-30. operating cash flow − capital expenditureOperating cash flow: −$34.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-13, accession 0001558370-25-011307. Derived: 6-month figure less the 3-month figure.Capital expenditure: $75.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-08-13, accession 0001558370-25-011307. Derived: 6-month figure less the 3-month figure.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$178.0mOperating margin −38.6%
Diluted EPS−$0.05, FY2024
Free cash flow−$74.1m, FY2024
Adaptimmune Therapeutics PLC, key figures for the last five fiscal years
Line itemUnitFY20202020-12-31FY20212021-12-31FY20222022-12-31FY20232023-12-31FY20242024-12-31Shape over the periods
Revenue$m4.0Revenue, FY2020, twelve months to 2020-12-31$4.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2023-03-06, accession 0001558370-23-002907.Report this figure6.1Revenue, FY2021, twelve months to 2021-12-31$6.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-03-06, accession 0001558370-24-002537.Report this figure27.1Revenue, FY2022, twelve months to 2022-12-31$27.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-24, accession 0001558370-25-003544.Report this figure60.3Revenue, FY2023, twelve months to 2023-12-31$60.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-24, accession 0001558370-25-003544.Report this figure178Revenue, FY2024, twelve months to 2024-12-31$178.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-24, accession 0001558370-25-003544.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%(3370.5%)Operating margin, FY2020, twelve months to 2020-12-31. operating income / revenueOperating income: −$133.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2023-03-06, accession 0001558370-23-002907.Revenue: $4.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2023-03-06, accession 0001558370-23-002907.Report this figure(2638.6%)Operating margin, FY2021, twelve months to 2021-12-31. operating income / revenueOperating income: −$162.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2024-03-06, accession 0001558370-24-002537.Revenue: $6.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-03-06, accession 0001558370-24-002537.Report this figure(604.0%)Operating margin, FY2022, twelve months to 2022-12-31. operating income / revenueOperating income: −$164.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-24, accession 0001558370-25-003544.Revenue: $27.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-24, accession 0001558370-25-003544.Report this figure(231.8%)Operating margin, FY2023, twelve months to 2023-12-31. operating income / revenueOperating income: −$139.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-24, accession 0001558370-25-003544.Revenue: $60.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-24, accession 0001558370-25-003544.Report this figure(38.6%)Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: −$68.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-24, accession 0001558370-25-003544.Revenue: $178.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-24, accession 0001558370-25-003544.Report this figure
Net margin%(3286.8%)Net margin, FY2020, twelve months to 2020-12-31. net income / revenueNet income: −$130.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2023-03-06, accession 0001558370-23-002907.Revenue: $4.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2023-03-06, accession 0001558370-23-002907.Report this figure(2571.0%)Net margin, FY2021, twelve months to 2021-12-31. net income / revenueNet income: −$158.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-03-06, accession 0001558370-24-002537.Revenue: $6.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-03-06, accession 0001558370-24-002537.Report this figure(609.5%)Net margin, FY2022, twelve months to 2022-12-31. net income / revenueNet income: −$165.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-24, accession 0001558370-25-003544.Revenue: $27.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-24, accession 0001558370-25-003544.Report this figure(188.9%)Net margin, FY2023, twelve months to 2023-12-31. net income / revenueNet income: −$113.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-24, accession 0001558370-25-003544.Revenue: $60.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-24, accession 0001558370-25-003544.Report this figure(39.8%)Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: −$70.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-24, accession 0001558370-25-003544.Revenue: $178.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-24, accession 0001558370-25-003544.Report this figure
Diluted EPS$ per share(0.15)Diluted EPS, FY2020, twelve months to 2020-12-31−$0.15 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2023-03-06, accession 0001558370-23-002907.Report this figure(0.17)Diluted EPS, FY2021, twelve months to 2021-12-31−$0.17 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-03-06, accession 0001558370-24-002537.Report this figure(0.17)Diluted EPS, FY2022, twelve months to 2022-12-31−$0.17 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-03-24, accession 0001558370-25-003544.Report this figure(0.09)Diluted EPS, FY2023, twelve months to 2023-12-31−$0.09 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-03-24, accession 0001558370-25-003544.Report this figure(0.05)Diluted EPS, FY2024, twelve months to 2024-12-31−$0.05 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-03-24, accession 0001558370-25-003544.Report this figure
Free cash flow$m(55.9)Free cash flow, FY2020, twelve months to 2020-12-31. operating cash flow − capital expenditureOperating cash flow: −$53.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2023-03-06, accession 0001558370-23-002907.Capital expenditure: $2.3m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2023-03-06, accession 0001558370-23-002907.Report this figure2.2Free cash flow, FY2021, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: $10.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-03-06, accession 0001558370-24-002537.Capital expenditure: $8.6m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2024-03-06, accession 0001558370-24-002537.Report this figure(171)Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: −$141.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-24, accession 0001558370-25-003544.Capital expenditure: $29.5m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-03-24, accession 0001558370-25-003544.Report this figure(146)Free cash flow, FY2023, twelve months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: −$140.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-24, accession 0001558370-25-003544.Capital expenditure: $4.7m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-03-24, accession 0001558370-25-003544.Report this figure(74.1)Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$73.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-24, accession 0001558370-25-003544.Capital expenditure: $886.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-03-24, accession 0001558370-25-003544.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Dec 2024 to Nov 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

None of the funds in coverage reports a position in this company in its latest 13F.

Recent filings

All 804 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Adaptimmune Therapeutics PLC, recent filings
FiledFormWhat it isAccession number
2025-10-2007:50 ET8-K3.01 Delisting notice; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001104659-25-100618
2025-09-2616:30 ET8-K3.01 Delisting notice0001104659-25-093882
2025-09-1216:27 ET8-K3.01 Delisting notice0001104659-25-089558
2025-09-0816:05 ET8-K5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits0001558370-25-011925
2025-08-2916:30 ET8-K5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits0001558370-25-011820
2025-08-1918:53 ETSCHEDULE 13D/AOwnership report, active investor, amended0001072613-25-000670
2025-08-1516:30 ET8-K5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits0001558370-25-011616
2025-08-1416:31 ET8-K3.01 Delisting notice0001558370-25-011579
2025-08-1307:47 ET10-QQuarterly reportPeriod 2025-06-300001558370-25-011307
2025-08-1307:37 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001558370-25-011304

Latest annual report

Form 10-K for the fiscal year ended Dec 31, 2024Filed Mar 24, 2025. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Not in this season’s league. The league lists companies whose quarter has ended and whose results are not yet filed.This season’s league

About the filer

CIK
1621227
Tickers
ADAPY
Exchange
OTC
SIC code
2836 Biological Products, (No Diagnostic Substances)
Sector
Healthcare
Fiscal year ends
Dec 31
Incorporated in
X0
Filer category
Non-accelerated filer<br>Smaller reporting company
Former names
Adaptimmune Ltd (to 2015-03-17)

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:44 ET. Listed shows no prices and gives no investment advice.